Tuesday, Mar 02, 2021 - 12:40:40
35 results - (0.000 seconds)

based vaccines:

    MOSCOW, Feb 27 (.) – A Russian trial testing the effectiveness of revaccination with Sputnik V injection in protecting against new variants of the coronavirus is producing robust results, researchers said on Saturday. Last month, President Vladimir Putin ordered a review by March 15 of vaccines produced in Russia to determine their effectiveness against new variants that are spread in different parts of the world. “(A) recent study carried out by the Gamaleya Center in Russia showed that revaccination with the Sputnik V vaccine is working very well against new coronavirus mutations, including coronavirus strains from the UK and South Africa,” Denis Logunov said. , deputy director of the center that developed the immunization. The results of the trial are expected to be published soon, but this was the first indication of how the tests are going. No further details are available yet. So-called injections of viral vectors, such as...
    SAN FRANCISCO (KGO) -- San Francisco-based One Medical has terminated several employees after it was discovered they reportedly allowed ineligible patients to get vaccinated.A company spokesperson tells ABC that the allegations "perpetuates dangerous public misconceptions" about their COVID-19 vaccine protocols and that the "majority" of the people they vaccinate across the country are not their annual due-paying members, but have been "referrals from departments of health, including health care workers, nursing home patients, educators, and the homeless." They say One Medical has a "zero-tolerance policy" for any instance of preferential vaccine treatment to ineligible persons.VACCINE TRACKER: Here's how CA is doing, when you can get a coronavirus vaccineSan Francisco's Department of Public Health shared a letter with ABC7's Kate Larsen, that they sent to One Medial on Monday.In the letter, the city's COVID-19 command center directs One Medical to return 270 vials or 1,6000 doses of the Pfizer vaccine. DPH...
    SAN FRANCISCO (KGO) -- The COVID-19 pandemic is having a major impact across the world and also in cities across Northern California. The latest number of confirmed cases in the U.S. can be found at the CDC's 2019 Novel Coronavirus in the U.S. page. (The CDC updates the webpage on Monday, Wednesday and Friday.)Join anchor Kristen Sze for ABC7's daily interactive newscast about the novel coronavirus outbreak in the Bay Area and other hot topics. You can check here to stream the show Monday-Friday at 3 p.m. GET HELP: Resources and information about COVID-19 CA REOPENING TIERS: Map shows which counties can, can't reopen under Newsom's new 4-tier system LATEST LOCAL CASES: Updated number of COVID-19 cases, deaths in San Francisco Bay Area Here are the latest developments on the respiratory illness in the U.S.: Feb. 24, 20219:30 p.m.SF-based One Medical allegedly let ineligible people get vaccine, report...
    By TRAVIS LOLLER, Associated Press NASHVILLE, Tenn. (AP) — Tennessee is expanding eligibility for COVID-19 vaccinations to teachers, as well as people who are at least 65 years old, beginning Monday. Tennessee Health Commissioner Lisa Piercey announced the change in a virtual news conference on Tuesday while acknowledging that some counties have already begun vaccinating those groups. Piercey said some of the larger metro areas of the state are moving slower on vaccinating their populations. While the vaccines are allocated to Tennessee's 95 counties based on population, Piercey said some of the rural counties have a much lower rate of people wanting to be vaccinated and are developing a surplus. “That is why we are pushing further, faster in those counties with the phases, because they have people who are eligible but don't want it," Piercey said. Asked why the state doesn't allocate some of the unwanted vaccine to the...
    BOSTON (CBS) – CVS is now scheduling appointments for COVID-19 vaccinations at their pharmacies starting Friday, February 12. It will eventually be available at stores in 27 cities and towns in Massachusetts once they receive the vaccines from federal and state programs. The vaccines are only available through an appointment to those who are eligible, meaning those in Phase 1 or those age 75 and older in Phase 2 and their caregiver. The scheduling system opened on Thursday on CVS.com but you’ll have to be patient. Anyone looking to make an appointment in Massachusetts will be taken to a virtual waiting room to book your time for a shot. CVS said it will not provide a full list of participating locations because active stores will change regularly based on the vaccine supply. Those who don’t have online access can call customer service at 800-746-7287. Massachusetts is one of 11 states...
    As is now the usual case, there is good news and bad news in the battle to end this nation's COVID-19 pandemic via widespread vaccinations. The good news is very good indeed: The vaccines that have been developed so far are continuing to prove very effective at reducing deaths and serious illness, even when taking into account new variants of the virus that have popped up in the meantime. The New York Times' David Leonhardt puts some perspective on the numbers: Given a sample of 75,000 American adults, the virus "has killed roughly 150 of them and sent several hundred more to the hospital." Of the 75,000 people included in research trials for any of the five current vaccines, zero have died, and only a handful have been hospitalized. Even though researchers are counting up "effectiveness" percentages based on each vaccine's ability to prevent any symptoms of infection, Leonhardt notes,...
    SAN FRANCISCO (KPIX 5) – Facing criticism for a slow vaccine rollout, California’s plans to shift COVID-19 vaccine distribution to an age-based system is drawing a new set of critics. Like millions of Californians, 32-year-old Adam Byers suddenly found himself wondering when he’ll get his doses of the COVID-19 vaccine this week when the state vaccine tier distribution system changed. Byers suffers from a neuromuscular disorder that causes muscle weakness, even in his lungs. He should have been vaccinated in Tier 1C. “The lung weakness in particular makes me a high risk person for severe COVID in the event I would get infected. I am on extreme lockdown, for non-medical reasons, I have left the house once in the last 11 months,” Byers told KPIX 5. The updated vaccine schedule prioritizing seniors and then descending by age puts Byers and others in the disability community months away from their COVID-19...
    CHICAGO (CBS)– Chicago Public Schools, with the Chicago Department of Public Health, announced plans to begin vaccinating staff in mid-February. “CPS expects to begin receiving vaccines directly in mid-February, at which point it will begin a multi-month effort to offer vaccinations to eligible staff,” officials stated in a written release.  According to state health officials, vaccination eligibility expands to school staff and other employees in frontline essential roles beginning on January 25 in phase 1b. CPS officials said the amount of vaccines available for staff is “contingent upon federal vaccine allocations.” CPS staff will receive their vaccines at school-based sites. CPS also released a vaccination prioritization strategy that will ensure staff members with high exposure are vaccinated first. Within the three vaccination groups are subgroups of different roles based on “level of exposure” and “ability to reliably maintain mitigation measures.”
    ANKARA, Turkey (AP) — Turkish authorities have given the go-ahead for the emergency use of the COVID-19 vaccine produced by China’s Sinovac Biotch Ltd., paving the way for the rollout for Turkey’s vaccination program starting with health care workers and other high-risk groups. The health regulatory authority, the Turkish Medicines and Medical Devices Agency, said Wednesday it had approved the vaccine’s emergency use following examinations that lasted for 14 days. Health Minister Fahrettin Koca said he and members of Turkey’s scientific advisory council would receive the first shots later Wednesday. The vaccination program will begin on Thursday, starting with health care workers, he said. Copyright © 2021 The Associated Press. All rights reserved. This material may not be published, broadcast, written or redistributed.
    TEHRAN, Iran (AP) — Supreme Leader Ayatollah Ali Khamenei Friday banned Iran from importing of American Pfizer-BioNTech and Britain’s Astrazeneca Covid-19 vaccines, a reflection of mistrust toward the West. In a televised speech, he said the import of American and British vaccines were “forbidden,” referring to the surging death tolls from the virus in both countries. ”I really do not trust,” them, Khamenei said of those nations. “Sometimes they want to test ,” their vaccines on other countries, adding, “I am not optimistic (about) France,” either. However, Khamenei okayed the import of vaccines from other “safe” places, and remains supportive of Iran’s efforts toward producing a vaccine. The county began testing its vaccines on humans December. The product is expected to hit the local market in spring. Hardliners in Iran have longed opposed the U.S-made vaccines. Iran’s Revolutionary Guard in December rejected the use of foreign-made vaccines altogether. Gen. Mohammad...
    BEIJING/SINGAPORE (Reuters) - Fragmental releases of efficacy data for the COVID-19 vaccine developed by China's Sinovac could undermine confidence in the shot, experts warned, as several countries prepare for mass inoculations with the vaccine. Turkish researchers said on Thursday Sinovac's CoronaVac was 91.25% effective based on an interim analysis only to see a confusing readout the same day from Brazil which said the vaccine's efficacy was between 50% and 90%. Brazil has also delayed release of its efficacy data on the vaccine three times, as Sinovac seeks to consolidate data from global trials that include Indonesia, Turkey and Chile. The efficacy data is closely watched as many developing countries have signed deals to use the Sinovac vaccine which is easier to store and transport than rival shots developed by Pfizer and its partner BioNTech and Moderna. Experts say it's not unusual for a vaccine to show different efficacy rates in...
    The Centers for Disease Control and Prevention (CDC) provided guidance for distributing the coronavirus vaccine, and it appeared to take race into consideration. The Advisory Committee for Immunization Practices (ACIP), a CDC committee that provides recommendations for the implementation of vaccine programs, divided the population into groups and then offered suggestions as to which groups would be prioritized as the vaccines were made available. (RELATED: CDC Panel Recommends Pfizer Vaccine For People Over 16) The three main groups were adults over the age of 65, adults with high risk medical conditions and essential workers outside of the health care fields. Health care workers would be among the first to receive the vaccine because they were the most likely to be exposed to the virus on a regular basis. Screenshot/http://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2020-11/COVID-04-Dooling.pdf Those three groups were then evaluated based on three criteria that determined their need for access to the vaccine: science, implementation...
    The teams behind Britain’s Oxford/AstraZeneca vaccine and Russia’s Sputnik V vaccine will join forces to see if their coronavirus prophylactics work better in combination. The British vaccine had been touted by its supporters as having greater potential for worldwide application than its Pfizer and Moderna competitors due to comparatively low cost and purported ability to keep at the sort of temperatures achievable in an ordinary fridge. The Russian vaccine, while often neglected by the Western media, proved something of a rival in this respect, with its supporters pushing it as similarly cheap, easy to store, and supposedly more effective than the Oxford University offering. But Russian sniping at the British vaccine — derided as the “monkey vaccine” due to its being based on a chimpanzee adenovirus, while the Russians based theirs on two human adenoviral vectors — may be at an end, as AstraZeneca has accepted a Russian offer to run joint...
    If all goes well, Pfizers COVID-19 vaccine could start being distributed "within days," followed closely by Modernas after its hearing with the Food and Drug Administration on Dec. 17, Health and Human Services Secretary Alex Azar said Monday. "We are getting ready for rollout within days," Azar said on Fox News "Fox & Friends." "Thats why tomorrow President [Donald] Trump is hosting a vaccine distribution summit with many of our governors, our retail pharmacy chains and our distributors like McKesson, FedEx, and UPS to be very transparent and show the world how comprehensively we have planned out every aspect of this distribution." Azar said there will be 40 million doses of the Moderna and Pfizer vaccines at first, with 20 million to be held back for the second dose recipients will require. According to a Washington Post report, the 40 million doses are far short of the 300 million vaccines from AstraZeneca that had...
    Getting a COVID-19 vaccine to the right people could change the course of the pandemic in the United States. But who are the right people? As the decision looms for President-elect Joe Biden’s incoming administration, a new analysis argues for targeting the first vaccines to the same low-income Black, Hispanic and Native American households that have disproportionately suffered from the coronavirus. But no one at the federal level has committed to the idea, which would be a significant shift from the current population-based method adopted by Operation Warp Speed. “It’s not just a math problem. It’s a question of implementing a major social justice commitment,” said Harald Schmidt, a medical ethicist at the University of Pennsylvania, who compared the strategies with colleagues from the Massachusetts Institute of Technology and Boston College. The Associated Press conducted an independent analysis of the findings and worked with the team to estimate how many...
    Getting a COVID-19 vaccine to the right people could change the course of the pandemic in the United States. But who are the right people? As the decision looms for President-elect Joe Biden's incoming administration, a new analysis argues for targeting the first vaccines to the same low-income Black, Hispanic and Native American households that have disproportionately suffered from the coronavirus. But no one at the federal level has committed to the idea, which would be a significant shift from the current population-based method adopted by Operation Warp Speed. “It’s not just a math problem. It’s a question of implementing a major social justice commitment,” said Harald Schmidt, a medical ethicist at the University of Pennsylvania, who conducted the analysis of the strategies with colleagues from the Massachusetts Institute of Technology and Boston College. If the shots get to the right people, Schmidt argues, the benefits could extend to the...
    VIDEO4:0404:04How U.S. hospitals plan to distribute a Covid vaccineSquawk on the Street Hospital leaders in North Carolina and Ohio told CNBC on Tuesday they will soon be ready to distribute a coronavirus vaccine once emergency use authorization is granted by U.S. regulators. Atrium Health CEO Eugene Woods said the Charlotte-based health network is "locked and loaded" to combat the Covid-19 pandemic through vaccinations. "We have refrigeration units that can store up on Day One 300,000 vials," Woods said on "Squawk on the Street." "We also are training staff as we speak." Two coronavirus vaccines are awaiting clearance from the Food and Drug Administration, putting the complex logistics of distributing them into sharp focus. Following the emergency use application from Pfizer and BioNTech on Nov. 20, biotech firm Moderna submitted for the same authorization Monday after final trial data showed its vaccine was more than 94% effective in preventing Covid-19. "We...
    CHICAGO (WLS) -- Chicago-based United Airlines has begun shipping the first batches of the COVID-19 vaccine on charter flights, a source told ABC News.The source is familiar with the operation, according to ABC.The Federal Aviation Administration had already given the OK for the first mass air shipment of a COVID-19 vaccine.RELATED: Chicago expected to play pivotal role in COVID-19 vaccine transportation, distributionThis means thousands of coronavirus vaccine doses may already be in Chicago, ready to be deployed. But even as United Airlines confirmed that it has already begun shipping the first batches of Pfizer's COVID-19 vaccination, it may still be a couple of weeks before the FDA grants the drug emergency use authorization (EUA)."We, from a federal perspective, have promised a quick review of EUAs and [will] hopefully start sending out vaccines within 24 to 48 hours," U.S. Surgeon General Jerome Adams said on FOX News.The FAA said it established...
    Approximately 20 million Americans could begin receiving a coronavirus vaccine during the month of December, pending approval by the Food and Drug Administration (FDA) and the recommendation of the Centers for Disease Control and Prevention (CDC), the scientific head of Operation Warp Speed said Monday.  Dr. Moncef Slaoui told "Bill Hemmer Reports" that both Moderna and Pfizer will be filing for Emergency Use Authorization permits with the FDA within the next two weeks. The FDA, he explained, will then need "about a week or 10 days or so" to review both drugmakers' applications and decide whether or not to approve the accelerated release of their vaccines. "[A]t that moment we are ready and prepared to start distributing enough vaccine doses during the month of December to immunize about 20 million of the U.S. population ... on an ongoing basis," Dr. Slaoui told host Bill Hemmer. HOW MANY DOSES OF MODERNA'S CORONAVIRUS VACCINE WILL BE AVAILABLE? "We'll have 40 million...
    Pfizer and BioNTech announced this week that their vaccine was 90 percent effective at preventing symptomatic COVID-19 in clinical trials. The data is still preliminary and hasn’t been examined by independent researchers, but it’s good news for both this specific vaccine and for the other coronavirus vaccines in the pipeline — especially the ones that are based on the same genetic technology. “It’s extremely encouraging, in my view, not only for the Pfizer vaccine, but broadly speaking for the platform,” says Ross Kedl, an immunologist at the University of Colorado. Pfizer and BioNTech’s vaccine is made from genetic material called mRNA. mRNA carries instructions inside of cells and tells them to build proteins. The vaccine includes a specific piece of mRNA that contains instructions for how to make the spike protein of the coronavirus, which is the tiny bit that lets it bind to human cells. The vaccine spurs...
    The Food and Drug Administration released updated safety standards Tuesday for makers of COVID-19 vaccines despite efforts by the White House to block them, clearing the way for requirements that are widely expected to prevent the introduction of a vaccine before Election Day. In the new guidelines posted on its website, the FDA said vaccine makers should follow trial participants for at least two months to rule out any major side effects before seeking emergency approval. That standard had been a sticking point between the FDA and White House officials, who said it could unreasonably delay the availability of COVID-19 vaccines. President Donald Trump has repeatedly insisted a vaccine could be authorized before Nov. 3, even though top government scientists working on the effort have said that timeline is very unlikely. On Monday Trump said vaccines are coming “momentarily,” in a video recorded after he returned to the White House....
    Conservationists have launched a campaign to prevent the use of squalene, produced from shark liver oil, in COVID-19 vaccines. Shark Allies, a Los Angeles-based group dedicated to the conservation of sharks and rays, has started a Change.org petition to stop the use of the compound in vaccines to battle COVID-19. “Using sharks in COVID-19 vaccines is short-sighted, unpredictable, and unsustainable,” the petition says. “There are better alternatives. The industry must listen.” More than 58,000 people have signed the petition, which was launched about a month ago. “Shark squalene has been used as the main ingredient in some adjuvants to boost efficacy in vaccines,” the petition adds. “Squalene made from shark liver oil is used most commonly because it is cheap to obtain and easy to come by, not because it is more effective than other sources.” RARE ALL-WHITE SHARK FOUND: 'THE FISH OF A LIFETIME' An adjuvant is an ingredient in...
    By Stephen Nellis (Reuters) - Salesforce.com on Wednesday said it has adapted some of its business software to help healthcare organizations and government entities distribute vaccines for the novel coronavirus once they become available. The San Francisco-based company said the offering, called Work.com for Vaccines, will help cities, states and health-care groups track vaccine inventory levels, create online appointment portals and track how patients fare after being vaccinated. "All these vaccines have various levels of quality and efficacy. We all know that they're not all the same," Salesforce.com Chief Executive Marc Benioff told Reuters in an interview. "And so technology will be really critical in separating the wheat from the chaff in the vaccine." Multiple companies and nations around the world are racing to develop a vaccine to provide some degree of immunity to the novel coronavirus, which causes the disease COVID-19. The chief executive of GlaxoSmithKline, the world's largest...
    (Reuters) - VBI Vaccines Inc said on Monday it had entered into an agreement with Canada to develop a potential vaccine for COVID-19 by 2022 through mid-stage trials conducted exclusively in the country. Canada will contribute around 75% of the U.S.-based company's development costs and C$55.9 million ($42.2 million) for the project. VBI Vaccines said last month that together with the National Research Council Canada it was investigating the vaccine candidate, VBI-2900, in preclinical trials. As per the agreement, signed last week, the company's Ottawa-based unit is obligated to complete the vaccine development in or before the first quarter of 2022. There are currently no approved vaccines for COVID-19, but around 38 vaccines are being tested in humans around the world. ($1 = C$1.32) (Reporting By Mrinalika Roy in Bengaluru; Editing by Maju Samuel) Copyright 2020 Thomson Reuters.
    BERLIN (AP) — Germany says it is providing up to 750 million euros ($892 million) to support three domestic pharmaceutical companies that are developing vaccines against the new coronavirus. Science Minister Anja Karliczek said the government has already agreed to provide BioNTech and CureVac with 375 million euros and 230-million euros respectively to develop their mRNA-based vaccines. Talks with a third company, IDT Biologika, are expected to conclude soon, she said. The company is developing a vector-based vaccine that delivers a coronavirus protein into cells to stimulate the body’s immune response. The agreement with the three companies, which is tied to specific milestones, would guarantee Germany 40 million doses of vaccine. This comes on top of other vaccine supply agreements concluded through the European Union, of which Germany is a member. Copyright © 2020 The Associated Press. All rights reserved. This material may not be published, broadcast, written or redistributed.
    WARSAW, Poland (AP) — The Polish government is trying to secure more flu vaccines from international producers amid a national shortage fueled by higher demand during the coronavirus pandemic, Poland's health minister said Tuesday. Health Minister Adam Niedzielski said that Poland generally has very low flu vaccinations rates and is seeing a vaccine shortage now because orders for this fall and winter were based on last year's demand. Niedzielski said in an interview on Polish commercial station Radio Zet that his ministry held a meeting on Monday with representatives of key vaccine suppliers to explore the possibility of getting more vaccine shipments to Poland. During the last flu season, about 1.5 million people, or some 4% of Poland's population of 38 million were vaccinated for the flu, the health minister said. Some 100,000 unused vaccines must be disposed of, he said. “The vaccine procurement mechanism is always based on the...
    WARSAW, Poland (AP) — The Polish government is trying to secure more flu vaccines from international producers amid a national shortage fueled by higher demand during the coronavirus pandemic, Poland’s health minister said Tuesday. Health Minister Adam Niedzielski said that Poland generally has very low flu vaccinations rates and is seeing a vaccine shortage now because orders for this fall and winter were based on last year’s demand. Niedzielski said in an interview on Polish commercial station Radio Zet that his ministry held a meeting on Monday with representatives of key vaccine suppliers to explore the possibility of getting more vaccine shipments to Poland. During the last flu season, about 1.5 million people, or some 4% of Poland’s population of 38 million were vaccinated for the flu, the health minister said. Some 100,000 unused vaccines must be disposed of, he said. “The vaccine procurement mechanism is always based on...
    China showed off its coronavirus vaccines at a Beijing trade event. The vaccine was produced by Chinese companies Sinovac Biotech and Sinopharm. While neither drug is on the market, experts hope that they are approved after Phase 3 trials continue through the end of 2020. China has faced criticism over its handling of the virus and hopes the vaccine will help paint a different picture. Chinese President Xi Jinping said that any vaccine developed in the country would be a “global public good.” And the country’s Global Times tabloid reported that the price of the vaccines “will not be high.” AstraZeneca, who partnered with the University of Oxford to develop a drug, said that had paused their vaccine trials after a patient fell mysteriously ill. There are numerous coronavirus vaccine trials in many countries around the world. As of September, about 10 are in Phase 3 trials. Countries around...
    The Centers for Disease Control (CDC) has told public health agencies around the country that it is preparing two coronavirus vaccines. The vaccines, like most before it, are weakened forms of the virus intended to protect people against the coronavirus. Moderna and Pfizer are working on a type of vaccine that can be injected into muscle cells. The muscle then builds protein from the vaccine. Because the vaccines from the CDC and Moderna and Pfizer are still in testing stages, we don’t know for sure that they work, or if they’re safe. Vaccines must go through four phases of testing to ensure they’re safe. Phase 3, the current phase for Moderna and Pfizer, is when the vaccine is tested on people. Public health officials are racing to get a vaccine completed safely and effectively. The timeline is still unclear, but the CDC told agencies a limited dose could be...
    TORONTO/CHICAGO (Reuters) – Higher-profile COVID-19 vaccines designed in Russia and China share a potential shortcoming: They are centered on a typical chilly virus that several people have been exposed to, probably restricting their efficiency, some gurus say. FILE Photograph: A emblem of China’s vaccine specialist CanSino Biologics Inc is pictured on the firm’s headquarters in Tianjin, pursuing an outbreak of the coronavirus illness (COVID-19), China August 17, 2020. REUTERS/Thomas Peter/File Photo CanSino Biologics’ vaccine, permitted for military use in China, is a modified kind of adenovirus kind 5, or Advert5. The corporation is in talks to get emergency acceptance in a number of international locations in advance of finishing substantial-scale trials, the Wall Street Journal noted previous week. A vaccine created by Moscow’s Gamaleya Institute, approved in Russia before this thirty day period regardless of minimal screening, is dependent on 5 and a next considerably less frequent adenovirus. “The 5...
            by Danica Krka  LONDON, England (AP) — Pharma giants GlaxoSmithKline and Sanofi Pasteur have announced they will supply 100 million doses of an experimental COVID-19 vaccine to the United States as governments buy up supplies in hopes of securing a candidate that works. The United States will pay up to $2.1 billion “for development including clinical trials, manufacturing, scale-up and delivery” of the vaccine, the two companies based in Europe said in a statement. Sanofi will get the bulk of the funds. The U.S. government has a further option for the supply of an additional 500 million doses longer term as part of its Operation Warp Speed program. “The portfolio of vaccines being assembled for Operation Warp Speed increases the odds that we will have at least one safe, effective vaccine as soon as the end of this year,” U.S. Health and Human Services Secretary...
    Pharma giants GlaxoSmithKline and Sanofi Pasteur have announced they will supply 100 million doses of an experimental COVID-19 vaccine to the United States as governments buy up supplies in hopes of securing a candidate that works. The United States will pay up to $2.1 billion “for development including clinical trials, manufacturing, scale-up and delivery" of the vaccine, the two companies based in Europe said in a statement. Sanofi will get the bulk of the funds. The U.S. government has a further option for the supply of an additional 500 million doses longer term as part of its Operation Warp Speed program. “The portfolio of vaccines being assembled for Operation Warp Speed increases the odds that we will have at least one safe, effective vaccine as soon as the end of this year,” U.S. Health and Human Services Secretary Alex Azar said in a statement. “Today’s investment supports the Sanofi and...
1